Clinical trial oversight is changing.
For years, Sponsors have focused on demonstrating that oversight activities occurred: monitoring visits were completed, risks were reviewed, issues were escalated, and actions were documented. While these activities remain critical, evolving regulatory expectations, from ICH E6(R3) to EMA guidance on audit trail review, are shifting the conversation toward a more fundamental question:
Can you demonstrate why decisions were made and provide evidence that appropriate oversight occurred throughout the trial?
As clinical trials become increasingly digital, decentralized, and data-rich, the answer lies in a source of information that has historically been underutilized: audit trails.
Today, audit trail data has the potential to do far more than support compliance. It can help organizations create a defensible, traceable record of oversight decisions, one that strengthens inspection readiness, improves risk detection, and provides confidence in trial outcomes.
The Growing Challenge of Clinical Trial Oversight
Modern clinical trials generate more data than ever before.
Patient-reported outcomes, eCOA systems, wearable devices, decentralized trial technologies, electronic medical records, and third-party vendor platforms all contribute valuable information to study execution. While these innovations improve patient engagement and operational efficiency, they also create a more complex oversight environment.
Data no longer resides solely within traditional EDC systems. It moves across multiple platforms, vendors, and stakeholders, making it increasingly difficult to establish a complete picture of what happened, when it happened, and how risks were managed.
This complexity is compounded by the realities of decentralized trials. When patients complete assessments at home via ePRO applications, the site-centric monitoring model no longer provides sufficient visibility. Audit trail review becomes not just a compliance requirement, but the primary mechanism for detecting protocol non-compliance, unusual site behavior, and potential data integrity risks that would otherwise go undetected. (For a deeper look at how audit trail review applies in DCT environments, see our Advanced Audit Trail Review Techniques for Decentralized Clinical Trials webinar.)
At the same time, ICH E6(R3) and related guidance continue to emphasize risk-based quality management, data integrity, and proactive oversight. Sponsors are expected not only to identify potential risks but also to demonstrate how those risks were evaluated and addressed, and to do so in a way that can withstand regulatory scrutiny.
This creates a significant challenge: How do you prove your decisions at any point during a trial?
Moving Beyond Activity-Based Oversight
Many organizations still rely on oversight processes that focus heavily on documenting activities.
A monitoring visit was performed. A review meeting occurred. A risk was discussed. A query was resolved.
While these activities are important, they do not always provide sufficient evidence of the rationale behind decisions.
In an inspection, teams may be asked:
- Why was this issue investigated?
- What evidence triggered the review?
- How was risk assessed?
- Why was no action taken?
- What data supported the final decision?
Answering these questions requires more than process documentation. It requires objective evidence, and that evidence increasingly needs to exist before the inspection, not be reconstructed after it.
Audit Trails: An Untapped Source of Oversight Evidence
Every electronic system used in clinical research generates metadata.
Audit trails capture information about data creation, modification, timing, user activity, and system interactions. Historically, organizations viewed these records primarily as compliance artifacts that could be referenced when needed.
Today, leading Sponsors are beginning to recognize audit trails as something more valuable: a continuous source of oversight evidence.
When reviewed systematically, audit trail data can reveal:
- Delayed data entry
- Excessive modifications
- Recall-based reporting
- Unusual site behavior
- Protocol deviations
- Potential data integrity concerns
- Emerging operational risks
More importantly, audit trails provide objective information that can support and justify oversight decisions. Instead of relying solely on retrospective explanations, study teams can demonstrate the exact data patterns that triggered investigations and informed actions.
Why Manual Review Is No Longer Enough
The challenge is scale.
A single study can generate millions of audit trail records across multiple systems and vendors. Reviewing this information manually is often impractical and inefficient.
This is where advanced analytics change the picture. Statistical methods can identify patterns that would be nearly impossible to detect through manual review alone. One such approach, Time-Based Testing (TBT), analyzes data entry timestamps within ePRO and eCOA systems to detect scenarios where patients at a given site are submitting their diaries in unusually close proximity to each other. Deviations from expected patterns can signal data fabrication, site-level coaching, or protocol non-compliance.
This methodology formed the basis of CluePoints’ award-winning audit trail review project, recognized by the Association of Clinical Data Management (ACDM) for innovation in clinical data quality. (Read more about the ACDM Innovation Award.)
Other analytical approaches can identify:
- Sites with unusually similar reporting behavior
- Clusters of activity occurring at unexpected times
- Excessive correction patterns across patients or sites
- Atypical completion behaviors compared to study norms
These approaches allow study teams to focus their efforts where they matter most, while maintaining a documented and traceable record of how risk signals were identified and acted upon.
For real-world examples of how these methods work in practice, the eCOA Compliance & Audit Trail Review whitepaper walks through specific investigative scenarios drawn from actual study data.
Creating a Defensible Decision Trail
Inspection readiness is often discussed as an end-of-study activity. In reality, the strongest inspection readiness programs are built throughout the trial, one documented decision at a time.
A defensible decision trail connects every risk signal to the action it generated. It means that when an inspector asks “why was this site flagged?”, the answer isn’t a verbal explanation from a team member working from memory. It’s a documented record showing:
- What data pattern was detected, and when
- What analytical method identified it
- What investigation was initiated as a result
- What evidence was reviewed during the investigation
- What conclusion was reached and why
- What corrective action was taken, or why none was required
This kind of traceability isn’t just useful at inspection. It changes how teams work throughout the trial, because when decision-making is documented in real time, oversight becomes more systematic, more consistent, and more defensible at every stage.
Organizations that connect risk identification, audit trail analysis, investigation workflows, and documented decisions create something far more valuable than compliance documentation: a defensible decision trail that exists because the work was done well, not because it was prepared for review.
To see how this approach applies in practice with ePRO data, watch the ePRO Audit Trail Analysis webinar with GSK and Pfizer, where industry leaders share how they integrated Time-Based Testing into their centralized monitoring strategies.
The Future of Oversight Is Evidence-Based
As ICH E6(R3) and other regulatory expectations continue to evolve, Sponsors are reassessing how they approach audit trail review.
Organizations that view audit trails solely as a compliance requirement may struggle to extract meaningful value from the growing volume of metadata generated across modern trials.
Those that view audit trails as a source of oversight evidence have an opportunity to strengthen decision-making, improve risk detection, and enhance inspection readiness, not as a one-time project, but as a continuous capability built into how trials are run.
The goal is no longer simply to demonstrate that oversight activities occurred.
The goal is to prove that decisions were informed, justified, and supported by evidence.
Because in today’s clinical trial environment, oversight is no longer just about what you did.
It’s about proving it.
Ready to build a more defensible audit trail review strategy? Talk to a CluePoints expert.
